Literature DB >> 10864642

Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells.

S J Molesworth1, C M Lake, C M Borza, S M Turk, L M Hutt-Fletcher.   

Abstract

Entry of Epstein-Barr virus (EBV) into B cells is initiated by attachment of glycoprotein gp350 to the complement receptor type 2 (CR2). A complex of three glycoproteins, gH, gL, and gp42, is subsequently required for penetration. Gp42 binds to HLA class II, which functions as an entry mediator or coreceptor and, by analogy with other herpesviruses, gH is then thought to be involved virus-cell fusion. However, entry of virus into epithelial cells is thought to be different. It can be initiated by attachment by an unknown glycoprotein in the absence of CR2. There is no interaction between gp42 and HLA class II and instead a distinct complex of only the two glycoproteins gH and gL interacts with a novel entry mediator. Again, by analogy with other viruses gH is thought to be critical to fusion. To investigate further the different roles of gH in infection of the two cell types and to examine its influence on the assembly of the gH-gL-gp42 complex, we constructed two viruses, one in which the gH open reading frame was interrupted by a cassette expressing a neomycin resistance gene and the gene for green fluorescent protein and one as a control in which the neighboring nonessential thymidine kinase gene was interrupted with the same cassette. Virus lacking gH exited from cells normally, although loss of gH resulted in rapid turnover of gL and gp42 as well. The virus bound normally to B lymphocytes but could not infect them unless cells and bound virus were treated with polyethylene glycol to induce fusion. In contrast, virus that lacked the gH complex was impaired in attachment to epithelial cells and the effects of monoclonal antibodies to gH implied that this resulted from loss of gH rather than other members of the complex. These results suggest a role for gH in both attachment and penetration into epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864642      PMCID: PMC112138          DOI: 10.1128/jvi.74.14.6324-6332.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor.

Authors:  K M Haan; W W Kwok; R Longnecker; P Speck
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).

Authors:  G R Nemerow; R Wolfert; M E McNaughton; N R Cooper
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

Review 3.  Epstein-Barr virus and the B cell: that's all it takes.

Authors:  D A Thorley-Lawson; E M Miyashita; G Khan
Journal:  Trends Microbiol       Date:  1996-05       Impact factor: 17.079

4.  Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion.

Authors:  J S Greenspan; D Greenspan; E T Lennette; D I Abrams; M A Conant; V Petersen; U K Freese
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

5.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

Authors:  J D Fingeroth; J J Weis; T F Tedder; J L Strominger; P A Biro; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

6.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

7.  A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus.

Authors:  N Miller; L M Hutt-Fletcher
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

8.  Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis.

Authors:  T Gardella; P Medveczky; T Sairenji; C Mulder
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

9.  Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines.

Authors:  K Takada
Journal:  Int J Cancer       Date:  1984-01-15       Impact factor: 7.396

10.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

View more
  125 in total

1.  Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.

Authors:  A Janz; M Oezel; C Kurzeder; J Mautner; D Pich; M Kost; W Hammerschmidt; H J Delecluse
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates.

Authors:  Lucy Rasmussen; Aimee Geissler; Catherine Cowan; Amanda Chase; Mark Winters
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Fusion of Epstein-Barr virus with epithelial cells can be triggered by αvβ5 in addition to αvβ6 and αvβ8, and integrin binding triggers a conformational change in glycoproteins gHgL.

Authors:  Liudmila S Chesnokova; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

4.  Infection of Epstein-Barr virus in a gastric carcinoma cell line induces anchorage independence and global changes in gene expression.

Authors:  Aron R Marquitz; Anuja Mathur; Kathy H Y Shair; Nancy Raab-Traub
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-30       Impact factor: 11.205

5.  Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

Authors:  Wei Bu; Gregory M Hayes; Hui Liu; Lorraine Gemmell; David O Schmeling; Pierce Radecki; Fiona Aguilar; Peter D Burbelo; Jennifer Woo; Henry H Balfour; Jeffrey I Cohen
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

6.  Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion.

Authors:  Austin N Kirschner; Jasmina Omerovic; Boris Popov; Richard Longnecker; Theodore S Jardetzky
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.

Authors:  John G Kosowicz; Jaeyeun Lee; Brandon Peiffer; Zufeng Guo; Jianmeng Chen; Gangling Liao; S Diane Hayward; Jun O Liu; Richard F Ambinder
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

8.  Mutations of Epstein-Barr virus gH that are differentially able to support fusion with B cells or epithelial cells.

Authors:  Liguo Wu; Corina M Borza; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 9.  Imaging virus-associated cancer.

Authors:  De-Xue Fu; Catherine A Foss; Sridhar Nimmagadda; Richard F Ambinder; Martin G Pomper
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  The BDLF2 protein of Epstein-Barr virus is a type II glycosylated envelope protein whose processing is dependent on coexpression with the BMRF2 protein.

Authors:  Mindy Gore; Lindsey M Hutt-Fletcher
Journal:  Virology       Date:  2008-11-07       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.